BIODISTRIBUTION AND SHEDDING ANALYSIS FOLLOWING TREATMENT WITH RP1 ONCOLYTIC IMMUNOTHERAPY IN THE SKIN CANCER PATIENTS FROM THE IGNYTE CLINICAL TRIALJOURNAL FOR IMMUNOTHERAPY OF CANCERIF10.62022-11-071OA
IMMUNE BIOMARKER ANALYSIS OF RP1 IN COMBINATION WITH NIVOLUMAB IN PATIENTS WITH ADVANCED SOLID TUMORSJOURNAL FOR IMMUNOTHERAPY OF CANCERIF10.62022-11-071OA
GENERALIZABILITY OF PREDICTIVE VERSUS PROGNOSTIC INDICATORS FROM PUBLISHED TRANSCRIPTOMIC ASSOCIATIONS WITH TUMOR RESPONSE TO IMMUNE CHECKPOINT INHIBITIONJOURNAL FOR IMMUNOTHERAPY OF CANCERIF10.62022-11-070OA
A PHASE 1 CLINICAL TRIAL OF RP2, AN ENHANCED POTENCY ONCOLYTIC HSV EXPRESSING AN ANTI-CTLA-4 ANTIBODY, AS A SINGLE AGENT AND COMBINED WITH NIVOLUMABJOURNAL FOR IMMUNOTHERAPY OF CANCERIF10.62021-11-101OA
ARTACUS: AN OPEN-LABEL, MULTICENTER, PHASE 1B/2 STUDY OF RP1 IN SOLID ORGAN TRANSPLANT RECIPIENTS WITH ADVANCED CUTANEOUS MALIGNANCIESJOURNAL FOR IMMUNOTHERAPY OF CANCERIF10.62021-11-101OA
CERPASS: A RANDOMIZED, CONTROLLED, OPEN-LABEL, PHASE 2 STUDY OF CEMIPLIMAB ± RP1 IN PATIENTS WITH ADVANCED CUTANEOUS SQUAMOUS CELL CARCINOMAJOURNAL FOR IMMUNOTHERAPY OF CANCERIF10.62021-11-100OA
GENERALIZABILITY OF POTENTIAL BIOMARKERS OF RESPONSE TO CTLA-4 AND PD-1 BLOCKADE THERAPY IN CANCERJOURNAL FOR IMMUNOTHERAPY OF CANCERIF10.62020-12-100PREAI
INITIAL RESULTS OF A PHASE 1 TRIAL OF RP2, A FIRST IN CLASS, ENHANCED POTENCY, ANTI-CTLA-4 ANTIBODY EXPRESSING, ONCOLYTIC HSV AS SINGLE AGENT AND COMBINED WITH NIVOLUMAB IN PATIENTS WITH SOLID TUMORSJOURNAL FOR IMMUNOTHERAPY OF CANCERIF10.62020-12-107PREAI
AN OPEN-LABEL, MULTICENTER, PHASE 1/2 CLINICAL TRIAL OF RP1, AN ENHANCED POTENCY ONCOLYTIC HSV, COMBINED WITH NIVOLUMAB: UPDATED RESULTS FROM THE SKIN CANCER COHORTSJOURNAL FOR IMMUNOTHERAPY OF CANCERIF10.62020-11-098PREAI
个人简介
教育背景
工作经历
荣誉奖项
未登录.png){kind=icon}
未登录个人简介教育背景工作经历荣誉奖项
研究方向